Biotechnology company Celularity has received a non-compliance notice from Nasdaq after failing to submit its required quarterly 10-Q financial report on time. The company is now working to rectify the filing delays to maintain its exchange listing status.

NEXGEL anticipates achieving approximately $35 million in pro forma annual revenue following its acquisition of Celularity's wound segment.

Celularity is facing a Nasdaq listing rule breach after failing to submit its Q1 10-Q SEC filing.

Arbe Robotics and Celularity both received notifications from Nasdaq, with Arbe Robotics specifically informed about a minimum bid price deficiency, indicating potential compliance issues.

Biotechnology company Celularity has announced it has regained compliance with Nasdaq listing requirements following a previously delayed financial filing.

Celularity has successfully secured a strategic license deal for its biomaterials portfolio, with the agreement potentially valued at up to $35 million.